Three SARS-CoV-2 antibodies provide broad and synergistic neutralization against variants of concern, including Omicron.
Wang, S., Sun, H., Zhang, Y., Yuan, L., Wang, Y., Zhang, T., Wang, S., Zhang, J., Yu, H., Xiong, H., Tang, Z., Liu, L., Huang, Y., Chen, X., Li, T., Ying, D., Liu, C., Chen, Z., Yuan, Q., Zhang, J., Cheng, T., Li, S., Guan, Y., Zheng, Q., Zheng, Z., Xia, N.(2022) Cell Rep 39: 110862-110862
- PubMed: 35594869 
- DOI: 10.1016/j.celrep.2022.110862
- Primary Citation of Related Structures:  
7WHZ, 7WI0 - PubMed Abstract: 
The rapidly spreading Omicron variant is highly resistant to vaccines, convalescent sera, and neutralizing antibodies (nAbs), highlighting the urgent need for potent therapeutic nAbs. Here, a panel of human nAbs from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) convalescent patients show diverse neutralization against Omicron, of which XMA01 and XMA04 maintain nanomolar affinities and excellent neutralization (half maximal inhibitory concentration [IC50]: ∼20 ng/mL) ...